VEGFA and non-small cell lung carcinoma: Based on this preparation mechanism, L. Huang and colleague 39 explored the co-delivery strategy of gemcitabine monophosphate (GMP) and VEGF-targeted siRNA for non-small-cell lung cancer (NSCLC) therapy (Figure 5D).